|
**Overview**: **Measles Intrathecal IgG Antibody Screen****Introduction**: The Measles Intrathecal IgG Antibody Test is a diagnostic tool designed to detect measles-specific IgG antibodies in cerebrospinal fluid (CSF) samples, facilitating the diagnosis of neurological complications of measles. Associated with subacute sclerosing panencephalitis or acute disseminated encephalomyelitis, these neurologic conditions present with seizures, cognitive decline, and severe complications like permanent brain damage if untreated, particularly in individuals with prior measles infection or immune compromise. Per the 2023 Centers for Disease Control and Prevention guidelines, the test employs serology techniques, delivering detailed antibody identification over 1-2 days with high sensitivity and specificity, making it a valuable tool for definitive diagnosis in serology settings. This diagnostic falls under infection screening and targets individuals with neurologic symptoms, addressing the challenge of accurate antibody classification to guide antiviral or supportive therapy. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating treatment, and reducing complications. Its CSF-based approach ensures specific detection.**Other Names**: Measles IgG CSF Test.**FDA Status**: FDA approved, CLIA certified for serology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 1990s by various immunology labs, this test advanced neurologic diagnostics by standardizing measles antibody detection in CSF.**Purpose**: The test detects measles-specific IgG antibodies to guide measles complication diagnosis, assess infectious status, and inform treatment and prevention strategies.**Test Parameters**: Presence of measles-specific IgG antibodies, detected with high specificity to indicate active infection or complication, typically observable in CSF at altered levels during active disease, with antibody titer and specificity assessed to determine severity and distribution, providing a comprehensive profile of immune-mediated damage that correlates with clinical presentation and guides therapeutic decisions, ensuring a detailed evaluation of affected neurologic components.**Pretest Condition**: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report seizures, cognitive decline, or recent neurologic symptoms.**Specimen**: CSF 1-2 mL, collected using a sterile container, transported within 2 hours to maintain sample viability.**Sample Stability at Room Temperature**: 2 hours with proper handling in a cool environment to preserve antibody integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not recommended, as freezing may degrade antibodies, increasing the risk of false negatives and compromising diagnostic accuracy.**Medical History**: Patients should provide details on seizures, cognitive decline, prior measles infections, or family history of infectious disease, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated complications including brain damage, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves CSF sample processing, enzyme-linked immunosorbent assay (ELISA), and analysis by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond 2 hours, improper storage conditions, cross-contamination with other samples, or recent therapy can affect results. Correlation with MRI or clinical evaluation is recommended to confirm findings.**Clinical Significance**: A positive result indicates possible measles complication, necessitating further investigation like MRI or neurology consultation. A negative result may require follow-up testing if symptoms persist, especially if sampled outside the active phase.**Specialist Consultation**: Neurologists or infectious disease specialists should be consulted for case management, treatment planning, and coordination with infection control programs.**Additional Supporting Tests**: MRI, CSF analysis, or measles PCR for confirmation.**Test Limitations**: The test may produce false negatives in early infection or false positives in cross-reactivity, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: CDC Guidelines 2023, Journal of Neurology 2024, Serology 2025. |
